BTIG Research Downgrades Kura Oncology (NASDAQ:KURA) to Neutral

Kura Oncology (NASDAQ:KURA) was downgraded by BTIG Research from a “buy” rating to a “neutral” rating in a research report issued on Thursday,Briefing.com Automated Import reports.

Other equities research analysts have also issued research reports about the stock. JMP Securities restated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. Jefferies Financial Group cut their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Bank of America decreased their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.75.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $9.05 on Thursday. The firm has a fifty day simple moving average of $8.83 and a two-hundred day simple moving average of $15.16. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $703.73 million, a P/E ratio of -3.83 and a beta of 0.78. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same period in the previous year, the firm posted ($0.50) earnings per share. On average, analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock worth $100,739 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in Kura Oncology during the 3rd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after acquiring an additional 1,750 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology during the third quarter worth approximately $146,000. US Bancorp DE raised its stake in Kura Oncology by 184.5% in the 4th quarter. US Bancorp DE now owns 22,104 shares of the company’s stock valued at $193,000 after purchasing an additional 14,335 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Kura Oncology in the 3rd quarter valued at $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.